+Search query
-Structure paper
Title | Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants. |
---|---|
Journal, issue, pages | Antiviral Res, Vol. 212, Page 105576, Year 2023 |
Publish date | Mar 2, 2023 |
Authors | Ji Woong Kim / Kyun Heo / Hyun Jung Kim / Youngki Yoo / Hyun-Soo Cho / Hui Jeong Jang / Ho-Young Lee / In Young Ko / Ju Rang Woo / Yea Bin Cho / Ji Hyun Lee / Ha Rim Yang / Ha Gyeong Shin / Hye Lim Choi / Kyusang Hwang / Sokho Kim / Hanseong Kim / Kwangrok Chun / Sukmook Lee / |
PubMed Abstract | Rapid emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted an urgent need for the development of broadly applicable and potently neutralizing ...Rapid emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted an urgent need for the development of broadly applicable and potently neutralizing antibody platform against the SARS-CoV-2, which can be used for combatting the coronavirus disease 2019 (COVID-19). In this study, based on a noncompeting pair of phage display-derived human monoclonal antibodies (mAbs) specific to the receptor-binding domain (RBD) of SARS-CoV-2 isolated from human synthetic antibody library, we generated K202.B, a novel engineered bispecific antibody with an immunoglobulin G4-single-chain variable fragment design, with sub- or low nanomolar antigen-binding avidity. Compared with the parental mAbs or mAb cocktail, the K202.B antibody showed superior neutralizing potential against a variety of SARS-CoV-2 variants in vitro. Furthermore, structural analysis of bispecific antibody-antigen complexes using cryo-electron microscopy revealed the mode of action of K202.B complexed with a fully open three-RBD-up conformation of SARS-CoV-2 trimeric spike proteins by simultaneously interconnecting two independent epitopes of the SARS-CoV-2 RBD via inter-protomer interactions. Intravenous monotherapy using K202.B exhibited potent neutralizing activity in SARS-CoV-2 wild-type- and B.1.617.2 variant-infected mouse models, without significant toxicity in vivo. The results indicate that this novel approach of development of immunoglobulin G4-based bispecific antibody from an established human recombinant antibody library is likely to be an effective strategy for the rapid development of bispecific antibodies, and timely management against fast-evolving SARS-CoV-2 variants. |
External links | Antiviral Res / PubMed:36870394 / PubMed Central |
Methods | EM (single particle) |
Resolution | 3.1 Å |
Structure data | EMDB-33734, PDB-7yc5: |
Chemicals | ChemComp-NAG: |
Source |
|
Keywords | VIRAL PROTEIN/IMMUNE SYSTEM / spike protein / antibody / bispecific antibody / VIRAL PROTEIN-IMMUNE SYSTEM COMPLEX |